-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $460

Benzinga·10/12/2026 13:22:01
Diffusion vocale
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $455 to $460.